payers’ decisions will
depend on monitoring costs, marginal production costs, and the utility patients will derive
from treatment. In this context, a payer will prefer a MEA when the cost of treating a
patient who should not be treated is high and the monitoring costs relatively low; on the
other hand, if the treatment costs are low, a payer will prefer a non-MEA